Rapamycin - Effects on Alzheimer's and Cognitive Health

This study is testing whether rapamycin (an FDA-approved drug currently used to prevent organ rejection after transplant) can slow down cognitive decline in people with early Alzheimer's disease or mild cognitive impairment. Rapamycin has shown promise in animal studies at extending healthy lifespan and reducing Alzheimer's-related changes in the brain. **You may be eligible if...** - You are 55 to 89 years old - You have a diagnosis of mild cognitive impairment (MCI) or early Alzheimer's disease - A brain scan (amyloid PET) shows the protein buildup associated with Alzheimer's - Your blood counts, liver, kidney, and blood sugar levels are within normal ranges - You have a trusted person (family member or caregiver) who can attend visits with you **You may NOT be eligible if...** - You have diabetes or take diabetes medication - You have a history of skin ulcers or poor wound healing - You currently smoke or use drugs, or have a history of alcohol abuse - You take blood thinners (other than aspirin) - You have liver or kidney disease - You have had chemotherapy or radiation in the past year - You take certain medications that affect drug metabolism (CYP3A4 inhibitors or inducers) Talk to your doctor to see if this trial is right for you.